Previous product
Back to products
Tivdak (tisotumab vedotin-tftv)
CHF8,378.37
Next product
Inlyta (axitinib)
CHF839.80
Rybrevant (amivantamab-vmjw)
CHF7,507.36
Rybrevant (amivantamab-vmjw) is a prescription medicine used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that have EGFR exon 20 insertion mutations.
Reviews
There are no reviews yet.